Drug Profile
CMD 602
Alternative Names: CMD-602; WT1 TCR T cell therapy - Kuur TherapeuticsLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Imperial College of Science, Technology and Medicine; University College London
- Developer Kuur Therapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 23 Feb 2022 Discontinued - Phase-I/II for Acute myeloid leukaemia (Second-line therapy or greater) in Germany, Belgium, United Kingdom (IV)
- 23 Feb 2022 Discontinued - Phase-I/II for Chronic myeloid leukaemia (Second-line therapy or greater) in United Kingdom (IV)
- 23 Feb 2022 Discontinued - Phase-I/II for Myelodysplastic syndromes (Second-line therapy or greater) in Germany, Belgium, United Kingdom (IV)